Long-Acting Injectable Risperidone in the Treatment of Schizophrenia

PHASE3CompletedINTERVENTIONAL
Enrollment

382

Participants

Timeline

Start Date

September 30, 2006

Primary Completion Date

September 30, 2009

Study Completion Date

September 30, 2009

Conditions
Schizoaffective DisorderSchizophrenia
Interventions
DRUG

IM risperidone

long-acting injectable risperidone

DRUG

oral antipsychotic medication

doctor's choice (excluding other long-acting injectable medications but not specifying any particular oral agents or dosages)

Trial Locations (19)

10010

New York Harbor HCS, New York

19104

VA Medical Center, Philadelphia, Philadelphia

30904

VA Medical Center, Augusta, Augusta

33125

VA Medical Center, Miami, Miami

35404

VA Medical Center, Tuscaloosa, Tuscaloosa

44106

VA Medical Center, Cleveland, Cleveland

48201

John D. Dingell VA Medical Center, Detroit, Detroit

55417

VA Medical Center, Minneapolis, Minneapolis

60612

Jesse Brown VAMC (WestSide Division), Chicago

64128

VA Medical Center, Kansas City MO, Kansas City

76711

Central Texas Veterans Health Care System - Waco, Waco

77030

Michael E. DeBakey VA Medical Center (152), Houston

90822

VA Medical Center, Long Beach, Long Beach

98108

VA Puget Sound Health Care System, Seattle, Seattle

94304-1290

VA Palo Alto Health Care System, Palo Alto

06516

VA Connecticut Health Care System (West Haven), West Haven

02130

VA Medical Center, Jamaica Plain Campus, Boston

68105-1873

VA Medical Center, Omaha, Omaha

87108-5153

New Mexico VA Health Care System, Albuquerque, Albuquerque

All Listed Sponsors
lead

US Department of Veterans Affairs

FED

NCT00132314 - Long-Acting Injectable Risperidone in the Treatment of Schizophrenia | Biotech Hunter | Biotech Hunter